Cell-Free Tumor DNA Profiling via Liquid Biopsy

Revolutionize precision oncology with non-invasive, high- sensitivity tumor profiling for cancer biomarker discovery, clinical trial selection, and cancer monitoring.

Next-Generation Precision Oncology with Flexible Liquid Biopsy Solutions

Power your oncology research and clinical trials with unprecedented visibility into tumor dynamics and therapeutic response. Broad Clinical Labs’ Cell-Free Tumor DNA (cfDNA) Profiling via Liquid Biopsy service defines the new standard in cancer genomics, transforming costly, invasive tissue workflows into streamlined, high-sensitivity liquid biopsy solutions that deliver actionable insights.

Maximize every sample with our modular cfDNA profiling approach. Start with ultra-low-pass whole genome sequencing (ULP-WGS) for tumor fraction estimation (%TFx) and copy number alterations, then leverage the same sample for targeted deep sequencing with unique molecular identifier (UMI) error correction.

Research Applications

Cancer Biology Research

Drug Development

Clinical Translation

Unlock Precision Insights with Cell-Free Tumor DNA Profiling via Liquid Biopsy

Tailored Analysis with Maximum Sample Utility

Maximize insights from a single sample through cost-effective, modular workflows that enable researchers to customize cfDNA analysis depth and to scale sequencing based on study requirements.

Sample Flexibility and Accessibility

High-sensitivity liquid biopsy accommodates diverse specimen types including blood, plasma, urine, and CSF with minimal input requirements, overcoming the limitations of invasive tissue-based approaches.

Validated Precision with Publication-Ready Results

Leverage our rigorously validated liquid biopsy workflow, demonstrated in peer-reviewed publications with 97–100% sensitivity for tumor fraction detection, all processed in our CLIA-licensed and CAP-accredited facility.

Cell-Free Tumor DNA Profiling via Liquid Biopsy with Broad Clinical Labs

Service	Data Deliverables	What’s Included
Cell-free Tumor DNA Profiling via Liquid Biopsy	BAM file with data from ULP-WGS iChorCNA analysis to estimate %TFx (.seg file output) Additional analysis available on request, including somatic SNV/Indel calling for panels and exomes	Sample receipt & QC Library preparation Sequencing Data analysis & delivery

Project Workflow: Liquid Biopsy

Project onboarding
(contracting if required)

Regulatory Review
Quoting

Sample intake and QC
(extraction optional)

Receipt
DNA Extraction

See table above for sample input requirements

Library construction

UMI enabled

Sequencing

Illumina^® Sequencing technology

Data and report delivery
(bioinformatic analysis optional)

See table above for output data